TheraRadar
Data updated: Sep 20, 2026

IMITREX STATDOSE (AUTOINJECTOR) (sumatriptan succinate) · GSK

Approved 1992-12-28

IMITREX STATDOSE (AUTOINJECTOR) is FDA-approved to treat 1 condition (same as ONZETRA XSAIL).

3
Indications
--
Phase 3 Trials
1
Priority Reviews
33
Years on Market

Details

Status
Prescription
First Approved
1992-12-28
Routes
SUBCUTANEOUS
Dosage Forms
INJECTABLE

Companies

Active Ingredient: SUMATRIPTAN SUCCINATE

IMITREX STATDOSE (AUTOINJECTOR) Approval History

1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
62 FDA actions from 1992 to 2025 · 2 indication expansions
Dec 2025 SUPPL
Label · Labeling
Dec 2021 SUPPL
Label · Labeling
Mar 2021 SUPPL
Label · Labeling

What IMITREX STATDOSE (AUTOINJECTOR) Treats

1 indications

IMITREX STATDOSE (AUTOINJECTOR) is approved for 1 conditions since its original approval in 1992. These indications span multiple therapeutic areas including oncology, immunology, and more.

Same approved indications as ONZETRA XSAIL (same active ingredient).

Source: FDA Label
📋

Clinical Trial Registry

3 trials
Trial Sponsor ID Phase Status Title
NCT01381796 PROT-15-NP101-013 Ph 1 completed Compare PK and Bioavailability of 2 NP101 Patches With Oral Imitrex in Healthy Adults
NCT00723983 NP101-011 PROT-15-NP101-011 Ph 1 completed Phase I, Open Label, Single-Dose, Four Way Crossover Study to Compare the PK of NP101 With Oral Imitrex® (50mg) in Migraine Subjects During an Acute Migraine Attack and During a Non-Migraine Period
NCT00920686 results posted NXN-188-203 Ph 2 completed Study of NXN 188 for the Treatment of Migraine With Aura
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

IMITREX STATDOSE (AUTOINJECTOR) FDA Label Details

Indications & Usage

FDA Label (PDF)

IMITREX STATDOSE (AUTOINJECTOR) is FDA-approved to treat 1 condition — same approved indications as ONZETRA XSAIL.

Track IMITREX STATDOSE (AUTOINJECTOR) with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.